Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 0.53 |
| ▸ | CPT1A | P50416 | 3/20 | 0.53 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.51 |
| ▸ | CRAT | P43155 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682905 | 1.00 | CPT2 (0.53) | CPT2CPT1ACPT1BPLK1TAS1R3 | |
| SCHEMBL13409926 | 0.89 | PLK1 (0.53) | PLK1TAS1R3TAS1R1L3MBTL1MAPT | |
| SCHEMBL14070367 | 0.87 | PLK1 (0.51) | PLK1TAS1R3TAS1R1L3MBTL1MAPT | |
| SCHEMBL13409973 | 0.81 | PPARG (0.60) | CPT2CPT1ACPT1BPLK1TAS1R3 | |
| SCHEMBL10414822 | 0.79 | CRAT (0.58) | CPT2CPT1ACPT1BCRAT | |
| SCHEMBL10414824 | 0.79 | CRAT (0.58) | CPT2CPT1ACPT1BCRAT | |
| SCHEMBL3677864 | 0.79 | CPT2 (0.72) | CPT2CPT1ACPT1B | |
| SCHEMBL3677867 | 0.79 | CPT2 (0.72) | CPT2CPT1ACPT1B | |
| Trifluoroacetic Acid SCHEMBL3690941 | 0.79 | PPARG (0.52) | CPT2CPT1ACPT1BPLK1PPARG | |
| Trifluoroacetic Acid SCHEMBL3690945 | 0.79 | PPARG (0.52) | CPT2CPT1ACPT1BPLK1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.